SIGA - SIGA Technologies, Inc.
| Previous Close | 7.40 |
| Open | 7.43 |
| Bid | 5.20 x 800 |
| Ask | 8.05 x 800 |
| Day's Range | 7.22 - 7.47 |
| 52 Week Range | 4.21 - 8.47 |
| Volume | 212,474 |
| Avg. Volume | 294,316 |
| Market Cap | 589.628M |
| Beta (3Y Monthly) | 1.04 |
| PE Ratio (TTM) | 1.65 |
| EPS (TTM) | 4.46 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.00 |
- GlobeNewswire•2 months ago
Report: Developing Opportunities within NeuroMetrix, Sunesis Pharmaceuticals, Siga Technologies, NexPoint Residential Trust, Frequency Electronics, and Horizon Technology Finance — Future Expectations, Projections Moving into 2018
NEW YORK, Nov. 15, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Insider Monkey•2 months ago
How Immersion Corporation (IMMR) Stacks Up Against Its Market Cap Peers
Is Immersion Corporation (NASDAQ:IMMR) a good bet right now? We like to analyze hedge fund sentiment before doing days of in-depth research. We do so because hedge funds and other elite investors have numerous Ivy league graduates, expert network advisers, and supply chain tipsters working or consulting for them. There is not a shortage of […]
- GlobeNewswire•3 months ago
SIGA Announces Priority Review Voucher Transaction Totaling $80 Million
SIGA Technologies, Inc. (SIGA) (SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that it has entered into an agreement to sell its medical countermeasures priority review voucher (PRV) for a lump sum payment of $80 million. SIGA was awarded the PRV in July 2018 upon approval by the U.S. Food and Drug Administration (FDA) of oral TPOXX® for the treatment of smallpox. The PRV was awarded by FDA under a provision that encourages development of medical countermeasures enacted as part of the 21st Century Cures Act (Public Law 114-255).
- Benzinga•6 months ago
Siga Continues Rally After FDA Approves Smallpox Drug
Siga Technologies (NASDAQ: SIGA) announced the FDA's approval of TPOXX, or tecovirimat. The drug consists of an antiviral treatment designed to diminish the effects of smallpox upon outbreak and is the first approved treatment of its kind. The smallpox drug's importance is twofold.
- Benzinga•9 months ago
Benzinga's Daily Biotech Pulse: Achaogen Slumps On Mixed FDA Panel Vote, Pacific Biosciences Sinks On Q1 Miss
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks ( Stocks hitting 52-week highs on May 2 ) CASI Pharmaceuticals Inc (NASDAQ: CASI ) Eleven Biotherapeutics ...
- Benzinga•9 months ago
Benzinga's Daily Biotech Pulse: SIGA Rallies On FDA Panel Backing, Rigel And Gilead React To Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on May 1) ABIOMED, Inc. (NASDAQ: ABMD ) AveXis Inc (NASDAQ: AVXS ) (announced ...
- ACCESSWIRE•11 months ago
Emerging Developments: New Research on Siga Technologies and Tropicana Entertainment - A Look Ahead into 2018
NEW YORK, NY / ACCESSWIRE / February 27, 2018 / Latest key findings by Growth Market Report for all traders, shareholders, and investors of Siga Technologies Inc. (OTC PINK: SIGA) and Tropicana Entertainment ...
